Background and Purpose-Ischemic stroke is a known complication of acute myocardial infarction (AMI). Treatment of AMI has undergone great changes in recent years. We aimed to investigate whether changes in treatment corresponded to a lower incidence of ischemic stroke and which factors predicted ischemic stroke after AMI. Methods-Data were taken from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care
I
schemic stroke is a feared complication of acute myocardial infarction (AMI). Ischemic stroke is costly for society 1 and potentially disabling for the patient. Ischemic stroke after an AMI is also a strong predictor of death. [2] [3] [4] Stroke prevention after an AMI is, therefore, an important objective. During the past 10 years, there have been drastic changes in the treatment of AMI with a corresponding increase in the survival rate for these patients. Many of the new methods of treatment for AMI, both in hospital and in secondary prevention, could potentially have a positive effect on the incidence of ischemic stroke after AMI because some types of ischemic stroke and coronary heart disease share risk factors and have a similar pathophysiology. [5] [6] [7] There are, however, no conclusive data to whether modern treatment of AMI has reduced the risk of complicating ischemic stroke or not.
The stroke incidence after AMI has been examined in numerous studies, which have mostly been performed several years ago and have included fairly small patient populations or have had an unrepresentative patient selection. 8 In some studies, no discrimination has been made between ischemic and hemorrhagic stroke. 3, 9 Follow-up duration in the different studies has varied from in-hospital to 10 years after AMI. 8 In 2006, Witt et al 8 published a meta-analysis of studies of ischemic stroke after AMI. The studies in the meta-analysis were from the years 1978 to 2004, and the authors found a stroke rate of 11.1 (95% confidence interval [CI], 10.7-11.5) per 1000 patients with AMI during hospitalization, 12.2 (95% CI, 10.4-14.0) at 30 days after AMI, and 21.4 (95% CI, 14.1-28.7) at 1 year.
The aims of this study were to use a large population of unselected patients with AMI to define a high precision incidence of ischemic stroke after AMI; furthermore, to assess predictors of increased and decreased stroke risk reliably, including any connection with AMI treatment; and finally, to examine any changes in the risk of ischemic stroke after AMI during recent years. This study evaluates the acute phase by looking at the first 30 days after an AMI.
Methods
Patient data were taken from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admissions (RIKS-HIA), in which all patients treated in coronary care units are registered. Patient data are reported on case record forms that include >100 variables, which are recorded on admission, in hospital, and at discharge. The RIKS-HIA registry, which now is a part of the SWEDEHEART registry, has been described previously. 10, 11 In 1998, 58 of 81 hospitals with coronary care units (CCU) comprised the RIKS-HIA registry. 10 This number gradually increased during the studied period until 2008 when 74 of 74 hospitals with CCUs participated covering >95% of Swedish CCU admissions. 12 A total of 173 233 patients with their first registered myocardial infarction in the RIKS-HIA registry between the years 1998 and 2008 were included. The RIKS-HIA database became amalgamated with the Swedish national patient register (NPR) to identify ischemic stroke occurrences within 30 days of the AMI. The NPR register includes dates for admission and discharge, as well as diagnoses at discharge, for all hospital stays in Sweden. The International Classification of Diseases, Ninth Revision (433 and 434) and International Classification of Diseases, Tenth Revision (I63 and I64) codes for cerebral infarction were used. Both primary and secondary diagnosis International Classification of Disease codes were used for stroke diagnosis. The NPR misses information about principal diagnosis in 0.5% to 0.9% of hospitalizations in somatic care. 13 A diagnosis of stroke or transient ischemic attack in the NPR is correct in 98.6% of the cases. 13 The proportion of stroke events identified through the NPR (sensitivity) ranges from 84% to 98% in validation studies. 13 Clinical characteristics and medication on admission and at discharge were extracted from the amalgamated database. In the beginning of the study period, some variables had a significant proportion of missing data. The number of valid cases is presented for these variables to facilitate the assessment. Data for patients with and without stroke were summarized as means and percentages and were tested for differences with the χ 2 test for categorical data. Continuous variables were compared by means by using t test. The study period was divided Kaplan-Meyer analysis was performed for ischemic stroke-free survival during the different time periods and compared between groups using the log-rank test. Survival techniques were used for the analyses because ≈10% of the patients in the study population were dead within 30 days (n=17 645) of their myocardial infarction. To identify independent predictors of ischemic stroke after AMI candidate, variables were selected if they had been proven to predict increased or decreased risk in previous investigations. These variables were age, female sex, atrial fibrillation, and diabetes mellitus. 3, 9 Additional candidate variables were selected if they predicted an increased or decreased risk in a univariate Cox analysis. The candidate variables were then included in a multivariate Cox proportional hazards regression model. A 1:1 matched propensity score analysis with replacement was performed for the most important predictors of a reduced stroke risk to take bias further into account when estimating possible treatment effects. The statistical software psmatch2 in Stata13 was used. Age, sex, prior stroke, diabetes mellitus, atrial fibrillation, clinical signs of heart failure, ST-segment-elevation myocardial infarction (STEMI), fibrinolysis, coronary artery bypass grafting during hospitalization, and angiotensin-converting enzyme inhibitor treatment at discharge were included in the propensity scores. Percutaneous coronary intervention (PCI) during hospitalization, acetylsalicylic acid (ASA) treatment at discharge, statin treatment at discharge, and P2Y12 inhibitor treatment at discharge were only included in the propensity score when not considered the treatment variable of interest. Furthermore, the established congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or TIA (CHADS2) and congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or TIA, vascular disease, age, sex category (CHA2DS2-VASc) risk scores were used to assess the risk of ischemic stroke within 30 days.
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Results
From a total of 173 233 patients, 3571, 2.1% (95% CI, 2.0%-2.2%) developed an ischemic stroke within 30 days. Baseline characteristics are presented in Table 1 . Body mass index, blood pressure, cholesterol, prior renal failure, prior dialysis, and prior chronic obstructive pulmonary disease did not differ between the groups, stroke, and no stroke. The average patient with stroke was older, 76.1 years versus 71.1 years for the average no stroke patient. A larger proportion of patients with stroke were women, 45.0% versus 36.6%. The incidence of previous stroke stands out as being the variable with the largest difference between the 2 groups, 29.0% of the patients with stroke had a previous stroke versus 10.7% in the nonstroke group. Patients with stroke were more likely to have diabetes mellitus 25.2% versus 19.2% and correspondingly had slightly higher plasma glucose. There were less significant differences in heart rate and in the proportions of previous AMI, previous hemorrhagic stroke, and previous peripheral arterial disease. Table 2 shows the patient population divided into 5 time periods. In the early periods, especially 1998 to 2000, there AMI indicates acute myocardial infarction; BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; P-cholesterol, plasma-cholesterol; PCI, percutaneous coronary intervention; P-glucose, plasma-glucose; P-LDL, plasma-low-density lipoprotein; and STEMI, ST-segment-elevation myocardial infarction.
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was a substantial amount of missing data for some variables, which makes them less applicable for this period. During the entire period, there was a decreasing trend in the proportion of patients with a prior AMI, an STEMI, atrial fibrillation, or clinical signs of heart failure during hospitalization. Furthermore, there was a marked shift from thrombolysis to PCI as reperfusion method. Medication on admission and at discharge is presented in Tables 3 and 4 . Patients with stroke had more often prescriptions of β-blockers, angiotensin-converting enzyme inhibitors, and ASA on admission compared with the nonstroke group. Over time, both groups had an increase in statin medication on admission. At discharge, the patients with stroke were less likely to have ASA, P2Y12 inhibitors, statins, and β-blockers prescribed. In both groups, the prescription at discharge of all studied drugs increased, especially statins and P2Y12 inhibitors.
The incidence of ischemic stroke within 30 days after AMI was significantly lower in the latter time periods AMI indicates acute myocardial infarction; BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; P-cholesterol, plasma-cholesterol; PCI, percutaneous coronary intervention; P-glucose, plasma-glucose; P-LDL, plasma-low-density lipoprotein; and STEMI, ST-segment-elevation myocardial infarction. 2004 had stroke rates of 2.2% and 2.0% and was not significantly lower compared with the first time period. Table 5 shows the results of the multivariate Cox analysis. Predictors of increased risk for ischemic stroke risk after AMI were age, female sex, previous stroke, diabetes mellitus, atrial fibrillation, clinical signs of heart failure in hospital, STEMI, coronary artery bypass grafting during hospitalization, and angiotensin-converting enzyme inhibitor treatment at discharge. PCI during hospitalization, fibrinolytic treatment, ASA treatment at discharge, statin treatment at discharge, and P2Y12 inhibitor treatment at discharge were all independent predictors of reduced risk of ischemic stroke after AMI.
In matched propensity score analyses, PCI treatment, as well as treatment at discharge with ASA, statins, or P2Y12 inhibitors, remained significantly associated with a reduced risk of stroke (P=0.003, P<0.001, P=0.004, and P=0.010, respectively).
The CHADS2 and CHA2DS2-VASc scores were correlated with the risk for stroke with the notable exception of the highest score category in both systems. CHADS2 and CHA2DS2-VASc score in relation to ischemic stroke is presented in the Figure (A) and (B) , respectively.
To examine the effect of hospital, the risk of stroke was compared between the first 58 hospitals that participated in the registry and the hospitals that joined later. There was no elevated risk of stroke among the original 58 hospitals that could explain the decline in incidence over time. The risk of stroke was 2.1% in both hospital categories (χ 2 P=0.059; linear-by-linear P=0.006).
Discussion
This is, by far, the largest study examining the trends in incidence and predictors of ischemic stroke after an AMI. By the use of a nationwide registry including consecutively admitted patients to CCU's for a period of 11 years, these issues could be outlined clearly. The incidence of ischemic stroke during the first 30 days after AMI was 2.1%. The incidence is in the higher range of what we expected to find based on earlier studies. 3, 8, 9, 16 This could be attributed to a more representative patient population illustrated by the higher average age. The incidence of ischemic stroke during the first 30 days after AMI was reduced during the studied period of time from 2.2% in 1998 to 2000 to 2.0% in 2007 to 2008 (P=0.02). 
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This reduction in incidence of stroke after AMI coincides with the increased use of PCI, statins, P2Y12 inhibitors, and ASA, all of which were independent predictors of a reduced stroke risk (Table 5) . At the same time, the independent predictors of increased stroke risk were all fairly stable during the period, except for the use of angiotensin-converting enzyme inhibitors at discharge, which increased and the proportion of STEMI, atrial fibrillation, and clinical signs of heart failure during hospitalization, which decreased (Tables 2-4) . In this study, we confirmed some predictors from earlier studies. 3, 8, 9, 16, 17 Prior stroke, age, female sex, diabetes mellitus, and atrial fibrillation were independent predictors of increased risk of ischemic stroke. These predictors should now be indisputable. Earlier studies have shown that a previous AMI is associated with an increased risk of ischemic stroke. 3 In our multivariate Cox regression model, a previous AMI did not prove to be an independent predictor. The reason for this is unclear, but because the patients were selected based on their first entry in the RIKS-HIA register, the incidence of previous AMI declined during the studied period. Another explanation could be an improved secondary prevention treatment after AMI. Coronary artery bypass grafting during hospitalization also proved to be a predictor of increased stroke risk. This is in accordance with earlier studies of complications to coronary artery bypass grafting surgery 18, 19 and confirms the increased risk after AMI. STEMI was verified as a predictor of increased stroke risk, a finding previously reported by our group. 16 STEMI may be seen as a marker of myocardial infarction severity, a variable previously associated with increased stroke risk. 9, 20, 21 A previous heart failure diagnosis on admission was a predictor of increased risk (hazard ratio, 1.32; P<0.001) in a univariate Cox regression model (not shown) but associated with a decreased risk in the multivariable analysis. This may be explained by the renowned low accuracy of an out of hospital heart failure diagnosis. 22 Statin treatment proved to be an independent predictor of reduced stroke risk. This supports the results from the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study showing a reduction in stroke incidence during a 16-week follow-up. 23 In accordance with previous studies, we found no correlation between hyperlipidemia and stroke rates. 3, 9, 23 Fibrinolytic treatment and to a greater extent PCI proved to be associated with a lower risk of ischemic stroke in our multivariate analysis. This has not previously been established in a representative patient population. Previous studies have shown an association between early revascularization and a reduced incidence of stroke, but when adjusted for other risk factors, the statistical significance was lost. 24 The basis of this association could be the reduction in myocardial damage seen after thrombolysis and primary PCI. ASA has already been established as an independent predictor of stroke reduction after AMI, and this was confirmed in our study. 25 ASA is currently a cornerstone in secondary prevention after both AMI and ischemic stroke. We also found that P2Y12 inhibitors were associated with reduced risk of stroke, which is a new finding. Clopidogrel is well established in secondary prevention treatment after AMI, as well as after ischemic stroke, based on the Prevention Regimen For Effectively Avoiding Second Strokes (PRoFESS) trial. 26 In the Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY) study and Clopidogrel and Metoprolol in Myocardial Infarction Trial (COMMIT), there were trends of reduced stroke incidence, but neither study was designed to look at ischemic stroke as a singular end point. [27] [28] [29] The studies' designs, having an unrepresentative patient selection in CLARITY, which showed a borderline significant stroke reduction, as well as the absence of a loading dose of clopidogrel in COMMIT, make them less applicable.
Implications
The present results give a precise estimate of ischemic stroke risk in a representative population of patients with AMI and identify the relevant risk factors. There is a trend toward a lower incidence of stroke, which coincides with the implementation of more rigorous secondary preventive treatment after AMI. Several treatments were identified as predictors of reduced stroke risk, which highlights the importance of careful implementation of secondary prevention according to given guidelines.
The precise mechanisms behind the increased risk of stroke after AMI are not known. However, the predictors of stroke that we identified indicate that the degree of atherosclerosis, inflammation, and platelet reactivity are of importance. The absence of any connection between anticoagulation therapy in hospital and stroke occurrence does not support an important role of left ventricular thrombus, contrary to the opinion of most guideline authors. This somewhat controversial conclusion is, however, firmly supported by several large randomized trials. [30] [31] [32] Our data on CHADS2 and CHA2DS2-VASc score could be taken into consideration because of the high risk of ischemic stroke within 30 days for the patients in the higher risk score categories. Is there someway to optimize their treatment to reduce their risk? Further research should be done in this field. 
Limitations
The RIKS-HIA only includes patients with AMI hospitalized in CCU's. The registry thus contains ≈90% of patients <80 years of age and 65% of patients aged ≥80 years compared with the NPR that contains all patients with a hospital diagnosis of AMI. 33 This might lead to an underestimation of the stroke rate because older patients with AMI, based on previous studies and what we found in this study, are exposed to a higher stroke risk than younger patients.
Another limitation is that we could not determine at what time during hospitalization medication was started. ASA and P2Y12 inhibitors are usually given as soon as possible, whereas statins may be given later during the hospital stay.
Some of the variables in the analyses had a low number of valid cases. This was especially true in the early time periods for heart rate, blood pressure, plasma-glucose, and angiotensin receptor blocker, and through the entire period for body mass index, plasma-cholesterol, and plasma-lowdensity lipoprotein. When trying to establish independent risk factors with a Cox multivariate model, there is always the risk of confounders that is not taken into account because they were not recorded as variables in the database. Because we used nonrandomized data, the estimates of treatment effects may be biased, although we used advanced statistical methods to take the confounding into account.
Conclusions
The incidence of ischemic stroke during the first 30 days after AMI is ≈2.1% in an unselected patient population. The risk of ischemic stroke has decreased during the period 1998 to 2008. This decrease is associated with the increased use of ASA, P2Y12 inhibitors, statins, and reperfusion treatments,
